Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Marram Investment Management. This analysis is provided for institutional research purposes only and is not investment advice.
"Marram posted a steady +0.7% net return for Q3 (+3.0% YTD), actively trimming regional banks on expanding valuations to fund fresh allocations in out-of-favor payments and biopharma while maintaining a large 31% cash cushion."
In its 2025 3rd Quarter Letter, Marram Investment Management reported a +0.7% net return for the quarter, bringing YTD net returns to +3.0%. The fund generated solid performance from its Energy Infrastructure (MLPs) and Large Financials allocations, though Payment Technology was a YTD drag. During the quarter, the manager harvested gains in regional banking by exiting First Horizon and trimming Regions, lowering the sector's NAV allocation from 37% to 18% due to expanding valuations and easing credit standards. Proceeds were reinvested into payment companies (PayPal, Shift4) and a new 7% NAV basket in the out-of-favor Biopharma sector. Marram closed the quarter holding 31% in cash earning ~4% interest, maintaining high readiness to capitalize on selective market opportunities.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Marram posted a steady +0.7% net return for Q3 (+3.0% YTD), actively trimming regional banks on expanding valuations to fund fresh allocations in out-of-favor payments and biopharm...
Growth Outlook
Market outlook remains moderate conviction: Marram posted a steady +0.7% net return for Q3 (+3.0% YTD), actively trimming regional banks on expanding valuations to fund fresh allocations in out-of-favor payments and biopharm...
Risk Appetite
Risk appetite posture is moderate conviction: Marram posted a steady +0.7% net return for Q3 (+3.0% YTD), actively trimming regional banks on expanding valuations to fund fresh allocations in out-of-favor payments and biopharm...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Marram posted a steady +0.7% net return for Q3 (+3.0% YTD), actively trimming regional banks on expanding valuations to fund fresh allocations in out-of-favor payments and biopharm...
Forward Guidance
Forward guidance signal: Marram posted a steady +0.7% net return for Q3 (+3.0% YTD), actively trimming regional banks on expanding valuations to fund fresh allocations in out-of-favor payments and biopharm...
Language Signal
Tone analysis indicates above average conviction language: Marram posted a steady +0.7% net return for Q3 (+3.0% YTD), actively trimming regional banks on expanding valuations to fund fresh allocations in out-of-favor payments and biopharm...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Marram posted a steady +0.7% net return for Q3 (+3.0% YTD), actively trimming regional banks on expanding valuations to fund fresh allocations in out-of-favor payments and biopharm...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. Marram posted a steady +0.7% net return for Q3 (+3.0% YTD), actively trimming regional banks on expanding valuations to fund fresh allocations in out-of-favor payments and biopharm...
Time Horizon
Investment time horizon reflects a high conviction orientation. Marram posted a steady +0.7% net return for Q3 (+3.0% YTD), actively trimming regional banks on expanding valuations to fund fresh allocations in out-of-favor payments and biopharm...
